Primary biliary cirrhosis (PBC) is a chronic autoimmune cholestatic liver disease most commonly encountered in postmenopausal women; it is characterized by high-titer serum autoantibodies to mitochondrial antigens, elevated serum IgM, progressive destruction of intrahepatic bile ducts, and ultimately liver cirrhosis and failure. The cytopathic mechanisms leading to the selective destruction of intrahepatic cholangiocytes are still largely unknown. The current theory on the pathogenesis of PBC indicated that environmental factors might trigger autoimmunity in genetically susceptible individuals. In fact, genetic predisposition is critical to disease onset and progression, yet peculiar among autoimmune diseases, as indicated by the lack of a strong association with major histocompatibility complex haplotypes. Further, the recently reported concordance rate among monozygotic twins strenghtens the importance of genetic factors, while also indicating that additional factors, possibly infectious agents or xenobiotics, intervene to trigger the disease. In this review, the available data regarding the genetic factors associated with PBC susceptibility and progression, as well as the available evidence regarding the immunomediated pathogenesis of PBC, will be critically illustrated and discussed.
Introduction
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of unknown etiology that leads to a progressive nonsuppurative destruction of small and medium-sized intrahepatic bile ducts, and eventually to liver cirrhosis and failure. PBC is currently considered as presenting autoimmune features, despite the lack of direct evidence to support this assumption. Indeed, PBC has significant similarities with other autoimmune diseases, such as the presence of highly specific autoantibodies directed against mitochondrial (AMA) or nuclear (ANA) antigens and autoreactive T cells, the striking female predominance (estimated as a 9 : 1 female to male ratio), and the coexistence of other autoimmune diseaseas in approximately one-third of patients with PBC. 1 It is currently believed, based on experimental and clinical evidence, that PBC onset and progression are determined by environmental factors acting on genetically susceptible inidividuals. Both these components, in fact, appear to be necessary, albeit not being self-sufficient, to induce the autoimmune events that characterize PBC. In this article, we will attempt a critical approach to the available data on the genetic and immunological bases of PBC. In particular, we will concentrate on the crosstalk between these two apparently independent compartments of PBC etiopathogenesis, and will draw possible future scenarios.
Genetics of PBC
Tackling the genetic bases of complex diseases Similar to other autoimmune diseases, the pathogenesis of PBC should be regarded as complex or multifactorial, with multiple genetic and environmental factors interplaying to determine disease susceptibility and onset. 2 In fact, it is now clear that PBC genetic components are not related to a single gene mutation, nor the disease presents a complete penetrance, as indicated by data from monozygotic twin sets. Further, PBC is a complex disease that should be defined as rare, based on its prevalence in the general population (the highest reported being 402 cases per million 3 ). So far, data on the genetics of PBC are derived only from case-control studies designed to determine associations between specific polymorphic genes and the disease. 4 This approach, albeit meritory, raises some concerns due to its limits. In fact, association studies present several degrees of potential bias, including those caused by sample size and selection and control-matching criteria. For example, patients are often enrolled through tertiary referral centers and possibly over-represent the more advanced spectrum of PBC. As for controls, it is critical that these are matched also by race and geographical background to cases to minimize false-positive results based on population structure differences. The choice of candidate genes warrants further discussion; in most cases it is indicated by immunological features of the disease, as in the case of the major histocompatibility complex (MHC), or is often derived from data in other autoimmune conditions. Both these methods present several strengths; however, we note how the selection of genes with a solid rationale should in all cases be a priority in association studies. The overinterpretation of data is an additional critical issue in the interpretation of association data. To avoid false associations, all putative association results should be reproduced. It is disappointing to consider that the vast majority of proposed associations in complex diseases would fail this test. 5 Two more issues need to be addressed. First, there needs to be correction for multiple testing. Recent utilization of statistical approaches such as false discovery rate can obviate some of the problems with the conservative Bonferroni correction that may cause type 1 errors. 6 Lastly, one should also consider the publication bias that favors weakly positive associations over negative, yet rigorous, studies, thus often causing a duplication of efforts that could be easily avoided.
Familial PBC
Family members of patients with PBC have a higher risk of developing the disease, and the occurrence of multiple cases within the same family is referred to as 'familial PBC' 7 presenting variable frequency rates, possibly following a geoepidemiological pattern (Table 1) . Studies from the UK indicate that such frequency ranges between 1 and 2.4%, 8, 9 possibly increasing over the past decade, likely for the awareness of physicians and novel diagnostic tools. In the United States, Bach and Schaffner 10 observed a 4.3% familial prevalence in an analysis of 396 PBC cases both retrospectively and prospectively. Familial PBC was studied also in other countries and data indicated frequencies of 4.5% in Sweden, 11 3.8% in Italy, 12 and 5.1% in Japan, 13 in all cases calculated on the number of unrelated index PBC cases. More recently, a population-based study from Minnesota 3 identified 46 cases of PBC and reported a prevalence among family members higher than the general population. In the most recent series from the UK, 6.4% of patients with PBC had one familial case; in 1% of cases first-degree relatives were studied, leading to a 10.5 sibling relative risk. 14, 15 Finally, we have recently demonstrated that patients with PBC from the genetically peculiar population of Iceland did not present similar antimitochondrial patterns, while only one affected relative could be identified among 85 first-degree relatives. 16 Several studies have addressed the hypothesis that less specific immunological disturbances rather than a definitive diagnosis of PBC might in fact be shared by family members of patients. Interestingly, as many as 70% of PBC relatives had some degree of immunological impairment in studies from the early 1970s, 17, 18 while somewhat conflicting results came, more recently, from two studies of patterns of immunological disorders in family members. First, the Liver Group in Newcastle, UK found that 14% of first-degree relatives of 160 PBC cases had at least one autoimmune condition, with systemic sclerosis being the most frequent diagnosis. 19 In a smaller study from Brasil, only 5/100 first-degree relatives of 26 patients with PBC referred an autoimmune disease (only in one case PBC), while serum autoantibodies were detected in 11% of relatives, in most cases not accompanied by clinical signs of autoimmunity. 20 Twin studies Disease concordance rate in monozygotic and dizygotic twin pairs estimates the weight of genetic and environmental factors in the susceptibility to complex diseases. The concordance rates in monozygotic twins for autoimmune diseases range between 12% for rheumatoid arthritis 21 and 83% for celiac disease, 22 and are on average well below 50%. Until recently, only two case reports addressed the issue for PBC, with one describing a concordant 23 and the other a discordant 24 pair defined as monozygotic, although in both cases zygosity was not genetically proven. We have recently reported that concordance rates for PBC are 63% in monozygotic and null in dizygotic twins, with three out of eight monozygotic twin sets being discordant for disease occurrence. 25 Further, in some cases, the natural history of PBC as well as the comorbidities could vary significantly between concordant twins. The phenotypical discordance is particularly interesting as it could be caused by epigenetic factors, differences in exposure to environmental factors such as infections, 26 or xenobiotics, 27 as well as serendipity.
MHC and PBC
Strong associations with specific MHC alleles have been reported in many autoimmune diseases, in some cases constituting the gold standard for the diagnosis of undetermined cases. 28 Table 2 shows the results of association studies for human leukocyte antigens (HLA) in PBC onset and progression.
Class I HLA. In the past, studies performed on small series of subjects (between 21 and 75) have examined the association between HLA class I molecules and PBC susceptibility, [29] [30] [31] [32] [33] [34] [35] but the conclusions of such earlier reports were affected by several major flaws. First, the small patient populations evaluated in these studies may account for a limited statistical power of comparisons. Second, technical methods available at the time only allowed the analysis of limited members of HLA class I alleles, therefore raising the possibility of existing associations being underestimated. Nevertheless, our group reported that PBC is associated with various HLA-B alleles in a small proportion of the patients studied. 36 It is possible that positive association might be 41 This association was not confirmed in several other studies from different non-British European populations. 32, 35, 36, 42, 43 Moreover, other European studies suggested significant associations of PBC with DR3 29, 35 and DPB1*0301, 44 while the most recent study from the United States demonstrated an association between DRB1*08-DQA1*0401-DQB1*04 haplotype and PBC, albeit in a minority of patients. 40 Finally, studies from Japan failed to provide a consistent picture of HLA class II associations with PBC. 30, 31, 45 Interestingly, in a large series of Italian patients with PBC and controls, we observed a protective effect of the DRB1*11 allele against PBC. 36 Transporters associated with antigen processing (TAP1 and TAP2) also belong to the HLA class II family and have been studied in patients with PBC, since their products determine the transport of antigenic peptides across the endoplasmic reticulum prior to being loaded onto MHC molecules. However, possibly also due to the limited polymorphic nature, no association with PBC onset was found. 46 In summary, we can conclude that the picture of HLA class II involvement in PBC is quite complex. We could somehow assume that, similar to epidemiological data, the genetic background in PBC should also be regarded as following a geographical pattern.
Class III HLA. Data from association studies of polymorphisms of tumor necrosis factor alpha (TNF-a) in PBC are conflicting and a cautious interpretation is encouraged. 47 A polymorphism of the gene promoter region produces the more frequent variant TNF1, and the less frequent variant TNF2, 48 with TNF2 associated with increased transcription. [49] [50] [51] The prevalence of the TNF2 allele was reportedly protective against PBC onset, 52 while two other studies independently failed to detect any difference in genotype distributions between patients and controls. 15, 53 We note that, in the study from Tanaka et al, heterozygous patients had a significantly worse prognosis compared to homozygous TNF1/TNF1 patients, 53 as indicated by higher Mayo score value, currently the only validated index for PBC. 54 However, a study from Newcastle, UK did not confirm this alleged association. 15 Similarly, in the data obtained from Scottish, Brazilian, and Chinese series of patients with PBC, 43, 55, 56 and from a small population of patients undergoing liver transplantation for end-stage PBC, 57 no association of TNF genotypes with disease susceptibility or onset was observed.
Non-HLA genetic candidates in PBC High-throughput novel technologies have made the study of single-nucleotide polymorphisms (SNPs) of candidate genes the method of choice for association studies in PBC. In fact, the analysis of SNPs can define the linkage of specific loci or neighboring regions with disease traits. We note that, alongside the general considerations expressed above on the choice of candidate genes and populations, the study of SNPs should be more focused on coding variants (ie with demonstrated effects on phenotype) of genes, although this might exclude other SNPs possibly in linkage disequilibrium with genes important for disease onset. 5 A summary of association studies in PBC is illustrated in Table 3 .
Most studies of SNPs in PBC have been dedicated to molecules involved in regulating the immune response, thus hypothesizing that genomic differences at these levels might confer susceptibility to the loss of tolerance or to an aberrant immune response. Based on the expression of cytotoxic T lymphocyte antigen-4 (CTLA-4) by T cells following activation and the regulatory effect of this molecule on peripheral T-cell responses, SNPs of CTLA-4 were suggested as factors facilitating the breakdown of tolerance. Accordingly, the coding A49G SNP was found associated with PBC in a large British study 58 and in 77 Chinese patients with PBC, 59 while a smaller study from Brazil failed to confirm the association. 43 Several studied were further dedicated to SNPs of interleukins (IL), based on their active and critical role in the regulation of the immune response. Prompted by experimental data such as its dysregulated production by monocytes in PBC, 60 SNPs of IL-1 were studied in PBC. First, a study from the UK reported a significantly higher frequency of the IL-1B*1,1 genotype in patients with PBC compared to controls. The difference in the IL-1B*1,1 genotype distribution was even more marked in patients with early-stage disease, thus possibly indicating that IL-1 alleles might influence disease progression, albeit in a cross-sectional analysis. 41 The lack of association with PBC onset was also independently confirmed by Hungarian 61 and Chinese 62 researchers. The latter group, however, more recently described an association of PBC with the IL1-RN intron genotype comparing frequencies in 77 patients with PBC and 160 controls. 63 Further, based on experimental evidence of cytokine profiles and its involvement in the development of T helper 1 (Th1) cell responses, SNPs of the promoter region of the IL-10 gene were also analyzed in patients with PBC and controls. 55, 63, 64 Data from Italian and Japanese series demonstrated that both groups presented a higher prevalence of the À1082G/G genotype. 64 Such association was not confirmed in 77 Chinese patients with PBC. 62, 63 SNPs of the 1,25-dihydroxyvitamin D receptor (VDR) gene have been investigated in several studies, based on the dual role of vitamin D in the regulation of bone metabolism and inflammation. We note in fact that accelerated bone loss rates in patients with prolonged cholestasis (as in PBC) have been repeatedly reported, sometimes with conflicting results and in some cases with less than rigorous experimental designs. A significant association between BsmII polymorphisms of VDR and PBC was reported in patients with PBC from Germany, Hungary, and China, 61, [65] [66] [67] while the proposed association with bone loss 68 was not reproduced. 69 We believe that differences in the VDR gene might unravel further potential scenarios to help explain the infrequency of PBC in African-American women, 70 and could in turn support a possible role for sunlight exposure in PBC onset. Although fascinating, this assumption remains at present only a theory yet to be demonstrated.
Molecules responsible for bile acid transport and excretion in the biliary tree have been obvious targets in the search for genomic determinants of PBC onset.
Interestingly, SNPs and mutation of ATP-binding cassette (ABC) transporters involved in the secretion of bile from the hepatocyte 71 have been associated with intrahepatic cholestasis of pregnancy, 72 somehow reproducing the clinical picture observed in PBC. Pauli-Magnus et al 71 have recently investigated by gene sequencing the variants of genes coding for the two main ABC transporters with identification of 45 ABCB11 and 46 ABCB4 variants. Data, however, demonstrated that no mutation was associated with PBC.
As explained in depth below, recent studies from our group, combined with epidemiological evidence such as the geographical pattern of PBC prevalence, have suggested that PBC might result from the combination of a genetic background, with the necessary contribution of environmental factors, either infectious agents or xenobiotics (ie chemicals). 73 Prompted by this theory, we have recently investigated whether genetic variants leading to different xenobiotic metabolism or transport might in turn account for an increased risk of developing the disease. We therefore genotyped several polymorphisms of enzymes involved in the transport and metabolism of xenobiotics in 169 patients with PBC and 225 healthy controls. 74 Genes analyzed coded for cytochrome P450 (CYP) 2E1 and 2D6, multidrug resistance 1 (MDR1), and pregnane X receptor (PXR). Data demonstrated that no polymorphism was associated with PBC susceptibility, while a weak association of the CYP2E1 c2 allele with disease severity was observed in a small subgroup of patients.
Based on different rationales, several other genes have been investigated in the susceptibility to PBC in association studies. Among these, the distribution of specific alleles of CD40 ligand, 75 CD14, 76 endothelial nitric oxide synthase, 77 early T-lymphocyte activation 1/ osteopontin, 78 T-cell receptor C-beta2, 79 insulin-like growth factor 1, collagen-Ia1, 80 and toll-like receptor 9 81 did not differ between patients and controls. In some cases, however, a significant association with disease severity 77, 79 or bone loss 80 seemed evident.
Sex chromosomes in PBC: towards a new frontier? X-linked genes are well known to determine genderrelated characteristics at different levels, while also regulating the immune function, particularly to maintain tolerance. We were intrigued that major defects of the X chromosome, such as those leading to Turner's syndrome 82 or premature ovarian failure, 83 are commonly characterized as autoimmune conditions (particularly thyroid disease) and intrahepatic cholestasis. We then studied peripheral X monosomy rates in white blood cells from women with PBC and controls, including women with viral chronic hepatitis. We found a significantly higher frequency of monosomy of the X chromosome in peripheral leukocytes (particularly those of the adaptive immune response, ie T and B cells) in 84 compared to controls, and that such frequency was correlated with age in all groups, since it is well established that a certain degree of X chromosome loss is a physiological phenomenon. 85 Importantly, we ruled out that monosomic cells were in fact (microchimeric) male cells. 86 Moreover, these findings were also reproduced in two other autoimmune diseases characterized by female predominance and different organ specificity, such as systemic sclerosis and autoimmune thyroiditis, 87 thus disclosing different theoretical scenarios. First, autoimmunity in PBC could arise from a polygenic model with an X-linked major locus of susceptibility with genes escaping inactivation being involved; the female susceptibility might therefore as well derive from genes mapping on the Y chromosome. The second thesis states that PBC susceptibility might arise from a multigenic complex inheritance model in which specific Ylinked genes are protective. Conversely, X-linked genes would interact with other genes and be involved via a dose-dependent effect.
Based on the fact that autoimmunity affects predominantly postmenopausal women, 88 a role for the persistence of nonself (male) cells, likely of fetal origin (microchimerism), has been proposed in PBC, as in other autoimmune diseases. Fanning et al 89 demonstrated that detectable fetal DNA in liver samples years after pregnancy was associated with PBC, while other groups failed to recapitulate the hypothesis. 90, 91 The hypothesis, mostly based on data in other conditions, still awaits definitive confirmation or denial.
Is PBC a unique autoimmune disease? Where do we go from here? It should be clear, at this point, that PBC should be regarded as a 'peculiar, yet representative,' autoimmune condition from a genetic standpoint. First, PBC appears to have a unique genetic background compared to other human autoimmune diseases in which, for example, sound evidence of associations with specific MHC alleles has been provided. Data on alleles of class I, II, and III MHC in patients with PBC and controls have shown some degree of association, albeit weak, but was seldom independently confirmed or were limited to specific geographical areas. Second, we can surmise that PBC recognizes a multi-hit genetic background, with specific genes predisposing to the development of autoimmunity (first 'hit') and others determining natural history (second 'hit'). 41 Third, our twin study indicates that PBC concordance rates among monozygotic twins are the highest reported for autoimmunity, 25 with the exception of celiac disease, 22 which is also characterized by a strong genetic component as well as a defined environmental stimulus such as gliadin. On the other hand, PBC also presents some similarities with the genetics of other autoimmune diseases. First, as in the case of most autoimmune conditions, family members of patients with PBC have an increased risk of being diagnosed with the disease, or to present other autoimmune features as systematically reported in 1995. 7 More recently, the common finding of enhanced X monosomy also indicates common ground between PBC and autoimmunity in general.
We believe that future evidence should be derived from three possibly more extensive approaches. First, a worldwide effort should be dedicated to the collection of a large number of representative families with more than one member affected. Second, we encourage the use of novel gene microarray technologies in PBC samples, with particular attention paid to technical limitations and bias of the methods in use. 92 Lastly, a whole genome association scanning will definitively provide the best answer to our questions 93 if performed on a large series of well-selected cases and matched controls.
Immunopathogenesis of PBC
AMA High-titer serum AMA are sensitive markers for PBC, being detected in up to 95% of patient sera; 1 their prevalence and specificity depend largely on the diagnostic method used. Indirect immunofluorescence (IIF) on tissue sections is used for screening purposes, providing a limited sensitivity and, particularly at lower dilutions of sera, low specificity for PBC. 94 When AMA are tested with recombinant mitochondrial antigens (using immunoblotting or ELISA at research centers), the sensitivity and specificity of the test approaches in selected series 100%. 94 This is particularly important, since AMA positivity is one of the three diagnostic criteria for PBC, thus proving crucial in the clinical management of many cases. Serum AMA specifically recognize components of the 2-oxoacid dehydrogenase (2-OADC) family of enzymes located on the inner mitochondrial membrane, 95, 96 including epitopes within the E2 and E3BP components of the pyruvate dehydrogenase complex (PDC) and the E2 subunits of the 2-oxoglutarate dehydrogenase complex (OGDC-E2) and branched-chain oxoacid dehydrogenase complex (BCOADC-E2). Interestingly, AMA epitopes on different molecules are conformationally closely related and include in all cases lipoic acid 97, 98 attached to the lysine (K) residue within the amino-acid motif DKA. Whether lipoic acid is in fact necessary for the epitope recognition by AMA is not understood. 97, 99 From a clinical standpoint, AMA pattern or titer do not correlate with disease severity of prognosis; 100,101 similarly, patients with PBC lacking detectable AMA present clinical features similar to their AMA-positive counterparts. 102 These observations, alongside the numerous approaches that lead to the development of AMA not accompanied by PBC-like liver pathology in animal models, seem to militate against a direct pathogenic role of AMA in PBC. 103 Further, serum AMA seem to appear several years the onset of PBC in affected individuals. 104 ANA PBC-specific ANA IIF patterns are found in up to a third of patients and sometimes more commonly in AMAnegative cases. Such PBC-specific patterns include 'nuclear rim' and 'multiple nuclear dots', secondary to ANA directed against gp210 and nucleoporin 62 (within the nuclear pore complex, NPC) and the nuclear body protein sp100 and PML, respectively. 105 More recently, it has been suggested that small ubiquitin-like modifiers (SUMO) also constitute independent autoantigens specific for PBC, although anti-SUMO antibodies are found only in anti-Sp100-positive sera. 106 Indeed, cross-sectional and longitudinal studies on anti-NPC antibodies in PBC suggested that patients presenting such ANA positivity might present a more severe and rapidly progressing disease. 107, 108 Cellular immunity Autoreactive T cells. The study of liver samples from patients with PBC reveal several types of mononuclear cells in the proximity of affected bile ducts with CD4 þ and CD8 þ T cells as the most represented subpopulations. 109 The main epitope for autoreactive CD4 þ T cells in PBC has been mapped within PDC-E2, 110 particularly amino-acid residues 163-176 spanning across the inner lipoylated domain of the subunit. 111 Further, the PDC-E2 amino acids E, D, and K are essential for the recognition of the epitope by HLA-restricted T-cell clones, similar to that observed for AMA. PDC-E2 [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] -specific CD4 þ Tcell clones also react with other AMA-specific mitochondrial autoantigens, including the E2 subunits of OGDC and BCOADC, as well as E3BP. 112, 113 In all these molecules, interestingly, the epitopes include a lipoylated domain. The study of TCR b gene rearrangements of cell clones obtained from PBC liver biopsies demonstrated different degrees of oligoclonality of the infiltrating T cells. 114, 115 The use of TCR Vb or Jb genes by PDC-E2 [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] -reactive T-cell clones is also highly diverse with GXG or GXS motifs found within the complementaritydetermining region 3 (CDR3) of all T-cell clones. 116 When autoreactive T-cell frequencies are compared among different tissues of patients with PBC, PDC-E2 163-176 -reactive precursor T cells are 100-150-fold more represented in the hilar lymph nodes and the liver compared to the peripheral blood, possibly with changes in different disease stages. 112 Several lines of experimental evidence 117 suggest that CD8 þ cytotoxic T cells (CTL) participate in the immunopathogenesis of PBC. CTL lines were generated from patients with PBC using autologous immature dendritic cells pulsed with peptides selected by analyzing the mitochondrial antigens for amino-acid sequences containing HLA-A*0201-binding motifs; 118 further, these CTL lines produced IFN-g after restimulation with PDC-E2 inner lipoylated domain. In particular, Kita et al 118 indicate that the PDC-E2 amino-acid motif at positions 159-167 is an HLA-A*0201-restricted CTL epitope, and that autoreactive PDC-E2 159-167 -specific CD8
þ CTL are present in the peripheral blood of PBC patients. The same authors then used PDC-E2 159-167 -HLA-A*0201 tetramers and later reported that the frequency of PDC-E2 159-167 -specific CTL is approximately 10-fold higher in the liver than in the peripheral blood of patients with PBC, and that the precursor frequency of PDC-E2 159-167 -specific CTL in the peripheral blood was enhanced in early PBC stages. 118 Another HLA-A*0201-restricted CTL epitope was identified in a different sequence (amino acids 165-174) located within the inner lipoyl domain of PDC-E2 and partially overlapping with the previously described CTL and CD4 þ T-cell epitopes. 119 Innate immunity. Most research efforts have so far focused on the characterization of the adaptive immune response in patients with PBC. Important links between the adaptive and innate immune compartments have been recently described, thus making the study of the innate response critical to the understanding of autoimmunity. 120 For example, macrophages are capable of secreting proinflammatory cytokines that influence the adaptive response following stimulation by pathogenassociated molecular patterns (PAMPs). Data supporting a possible role of bacterial lipopolysaccharide (LPS) in PBC come from both human and animal studies. First, Ballot et al 121 studied sera from 36 patients with PBC and 560 controls, including several autoimmune conditions, for the presence of anti-lipid A (the immunogenic and toxic component of LPS) IgM and soluble CD14, and observed that 64% of PBC sera were positive for such antibodies in a PBC-specific fashion, correlating also with more florid histological lesions. Interestingly, lipid A accumulates in hepatocytes, Kupffer cells, and biliocytes in PBC livers. 122 These results confirmed a previous report conducted on a smaller series of patients and controls, 123 which supported an innate mechanism in the involvement of bacteria in the pathogenesis of PBC. These data have also further implications based on animal experiments. Masanaga et al 124 induced autoimmune cholangitis in mice by immunization with LPS and the mitochondrial autoantigens identified in PBC. The proposed role of innate alterations in PBC is supported also by a recent study demonstrating the enhanced expression of toll-like receptor 3 (belonging to the family of receptors binding PAMPs) in PBC liver cell subpopulations isolated by laser-capture microdissection. 125 Other studies have concentrated on specific cell types constituting the innate response. Natural killer T (NKT) CD1d-restricted cells are characterized by the expression of an invariant Va24JaQ TCR and the secretion of both IFN-g and IL-4 in response to stimulation with either anti-CD3 or a-galactosylceramide (aGalCer) presented by the nonpolymorphic, nonclassical MHC class I-like CD1 molecules. 126 Although NKT cells do not strictly belong to the innate compartment, their innate-like pattern and magnitude of activation indicate their inclusion in this part of our review. Human NKT cells have been implicated in a variety of immune responses, including human autoimmune diseases as well as their murine models. 127 NKT cells were quantitatively studied in PBC using a tetramer composed of human CD1d and a-GalCer, 126 and tetramer-restricted cells were significantly more represented in liver tissue compared to peripheral blood in PBC. Moreover, the frequency of NKT cells was higher in both these compartments when patients with PBC were compared to controls. At immunohistochemistry, NKT cells were commonly observed within portal tracts and liver parenchyma in patients with PBC or other liver diseases and healthy controls. 128 The involvement of natural immunity can be addressed as well, due to an activation of Toll-like Receptor 9 (TLR9) in B cells if stimulated by bacterial DNA CpG islands, 129 exiting in an increased IgM production, a common unexplained finding in PBC sera. These data, not secondary on the presence of TLR9 genetic polymorphisms, 130 also support the role of bacteria in the induction of PBC. No data are currently available regarding other cells of the innate compartment, such as monocytes/macrophages or polymorphonuclear cells.
Cytokines
The cytokine pattern characteristic of PBC is still debated. When tested by in situ hybridization, the PBC liver presents a significantly higher frequency of IFN-g-and IL-4 mRNA-positive cells compared to controls with, on the other hand, considerably fewer cells, with detectable levels of IL-4 mRNA than cells expressing IFN-g mRNA. 131 Moreover, IFN-g mRNA-positive cells are detected primarily around damaged bile ducts and in areas of piecemeal necrosis. We also note that mitogenstimulated T cells infiltrating the liver of PBC produce significantly higher levels of IL-4 and IL-10 compared to control T cells, but little IFN-g. 132 A consistent upregulation of IFN-g mRNA expression is also demonstrated by the study of RNA extracted from PBC liver. [133] [134] [135] Overall, these results appear to indicate that type 1 cytokines are the dominant pattern in PBC. However, an upregulation of specific type 2 cytokines, such as IL-5, IL-6, and IL-10, in PBC has also been postulated with conflicting results. [133] [134] [135] The mechanisms leading to T-cell recruitment in the liver of patients with PBC remain enigmatic. Both selective recruitment and selective retention appear to contribute to the resulting tissue enrichment. It is also possible that, at different stages, the migration of T cells into the liver is controlled by different pathways. Further, a process similar to that recently observed for a closely related disease such as primary sclerosing cholangitis should be verified in PBC. 136 
Mechanisms of tolerance breakdown and pathogenesis
In a dissertation about pathogenesis theories proposed in PBC, it should be remembered that all such theories are not independent from individual susceptibility (ie genetic background) and in some cases are not mutually exclusive. According to this view, PBC would then result from the interplay between genetic predisposition and one or more environmental factors leading to tolerance breakdown, and one or more of the proposed pathogenetic mechanisms leading to tissue-specific chronic inflammation and injury. Further, recent evidence on the possible mechanisms of tolerance breakdown has been provided using the murine strain SJL/J. 137 Although we maintain some concerns about the specificity of this model, 138 the data produced using these mice are intriguing and deserve to be discussed in the following sections.
Molecular mimicry
Molecular mimicry is the mechanism mediating autoimmunity induction by environmental factors that has received most research attention. 139 Briefly, we can define molecular mimicry as the sharing of epitopes on proteins from unrelated species that elicit an immune response crossreacting with human self antigens. In most cases, direct proof of causality cannot be achieved and hence mere crossreactivity cannot be ruled out, particularly when an animal model is not obtained. However, evidence of the possibility of this mechanism in PBC has been obtained in the SJL/J murine model by Jones et al, 140 who were able to induce a humoral and cellular autoimmune response by coimmunizing mice with both self and nonself (bovine) PDC-E2. Further, the possibility that molecular mimicry might lead to AMA and/or autoreactive T-cell appearance has been widely investigated, and humoral and cellular crossreactivity with prokaryotic antigens (particularly with the microbial respiratory chain enzymes such as PDC) has been reported for several viral and bacterial species, including Escherichia coli (the most widely studied species). 141 Interestingly, all these strains presented an ExDK motif within their mimicry epitopes. Once again, these crossreactivities might be secondary to the highly conserved sequence of PDC across all species, from eubacteria to mammals, 142 while the observation that human mitochondria likely originate from uptaken bacteria prompts further interest. Recently, we have proposed that the newly defined bacterial strain Novosphingobium aromaticivorans should be regarded as the best candidate yet for the induction of PBC through molecular mimicry. Several lines of evidence support our theory. First, the aminoacid sequences of four different proteins from N. aromaticivorans present one of the highest degrees of homology with the main AMA autoepitopes. 143 This has been confirmed by the cloning, sequencing, and expression of these four proteins by Padgett et al 144 that also defined the recombinant proteins using well-defined monoclonal antibodies. Second, although first isolated from sewage samples, N. aromaticivorans can be found in several environmental media, including water. Further, the bacterium does not cause disease in humans. Interestingly, moreover, a bacterium sharing a sequence homology over 99% with N. aromaticivorans has been demonstrated to be capable of modulating 17b-estradiol. 145 Lastly, and perhaps most importantly, the bacterium can metabolize a growing number of chemicals (xenobiotics); 146 for this reason, it is under study for bioremediation purposes. A role for halogenated xenobiotics in the induction of PBC has been supported by several studies from our group since the first report in 2001. 147 Based on these lines of evidence, we hypothesized that N. aromaticivorans or other strains sharing its major characteristics might be the missing link between xenobiotics and bacteria in the induction of PBC. Our serological study demonstrated a reactivity against two lipoylated proteins of 47 and 50 kDa molecular weight in 100% of anti-PDC-E2-positive and in a fraction of AMAnegative sera, regardless of the disease stage. Further, the immunoblotting positivity pattern observed was highly specific for PBC sera compared to sera from first-degree relatives of patients or controls with other autoimmune diseases. Importantly, the reactivity was 100-to 1000-fold higher than against E. coli, and still detectable at dilutions as high as 10 À6 in 23% of anti-PDC-E2-positive sera. 143 We also searched for the presence of the bacterial genome in feces from patients with PBC and non-PBC controls living in the same household, and were able to detect evidence of the specific 16S rRNA in approximately 25% of patients and controls. For purpose of completeness, we also note that researchers from one group have suggested that the presence of a novel human beta retrovirus in the liver and the lymph nodes might induce PBC, and reported that the culture of normal biliary epithelial cells (BECs) in the presence of a homogenate of PBC lymph nodes induced the expression of a PDC-E2-like antigen on cell membrane. 148 Although intriguing, we could not recapitulate this retroviral hypothesis. 149 Lastly, we note that auxiliary mechanisms have been postulated that might enhance the response to infectious agents, thus making mimicking proteins more immunogenic or the host more sensitive towards an aberrant immune response. A similar process can be hypothesized from data obtained using bacterial CpG motifs that can accelerate the breakdown of tolerance in SJL/J mice, 150 as well as induce the characteristic hyperIgM observed in PBC sera. 129 The role of xenobiotics in the scenario of molecular mimicry leading to PBC warrants further discussion. As mentioned above, xenobiotics are chemical compounds which might either modify or bind to self-molecules, thus altering their recognition by the immune system and possibly leading to the ultimate aggression of the similar native molecule. The presence of this molecule, in turn, is responsible for the chronic autoimmune reaction and injury in a self-alimenting process; this also implies that the trigger molecule might be no longer present at the moment of diagnosis. The main detoxifying organ is the liver, and this makes hepatocytes and BECs particularly prone to the action of ingested, injected, and inhaled chemicals. This paradigm is illustrated by an example. The appearance of serum autoantibodies following the intravenous administration of halotane, an inhalatory narcotic no longer used in anesthesiology, was described, 151 and these antibodies crossreacted with human PDC-E2. These findings seem to indicate that chemically induced modifications of the lipoylated domains of PDC-E2 could generate antibody production. In 2001, Long et al 147 replaced the inner lipoyl domain of PDC-E2 molecules with chemicals and tested the serologic reactivity of patients with PBC, and reported that serum AMA recognized three of the 18 novel molecules to a significantly higher extent than the native form. Further, our group demonstrated that the immunization of an animal model with a halogenated compound conjugated with a non-PDC-E2 amino-acid backbone led to serum AMA appearance, 152 and such serological finding was reversible when immunization was discontinued. 153 Importantly, the immunization of SJL/J mice with covalently modified self PDC-E2 could elicit the breakdown of both T-and B-cell tolerance. 154 Lastly, and most recently, one common everyday additive, 2-octynoic acid, was identified by Amano et al 155 as a common antigen in PBC sera.
Pathogenesis of the tissue injury
The major paradox of PBC is that the damage is highly localized and targets BECs lining only the small and medium-sized intrahepatic bile ducts (and the salivary gland epithelial cells in patients with also Sjogren's syndrome) despite the ubiquitous expression of the autoantigens. To address this issue, many efforts have been carried out to determine the unique features of this cell population. In fact, the epithelium of affected bile ducts presents a distinct morphology if compared to their larger counterparts, 156 also presenting different reactivity patterns when challenged with proinflammatory cytokines. 157 Further characterization indicated that, following stimulation with proinflammatory cytokines, BECs from patients and controls share the capability to increase the expression of the adhesion molecules ICAM-1, as well as the expression of MHC class I and II, TNF-a, INF-g, and IL-1 158 or VCAM-1 and LFA-1. 159, 160 In this case, BECs are similar to endothelial cells stimulated with atherogenic factors. 161 BECs could indeed act as antigen-presenting cells, since they express secondary costimulatory signals for T cells such as CD28, B7-1, or B7-2; 162 these data, however, were not supported by mRNA expression analyses. 163 Indeed, the hypothesis that these observations underlie an active role for BECs in their own destruction remains fascinating, yet to be proven.
The role of apoptosis in bile duct loss in PBC has been widely investigated, and, in most cases, data have indicated programmed cell death as a prominent mechanism involved in histological lesions of PBC. First, Harada et al 164 reported that BECs from patients with PBC are prone to apoptosis via the perforine/granzyme B pathway, and this process is enhanced by CD95/ CD95L binding. Further, BECs undergoing apoptosis overexpress CD40, Fas, and FasL. 165 Critical evidence for the role of apoptosis in PBC came from Joseph Odin et al, 166 who demonstrated the glutathionylation of the lysine lipoic acid moiety of PDC-E2 to be reduced by patient AMA and that this process is related to the expression of Bcl-2. Bcl-2 concentration in the cell was also correlated with the observation that PCD-E2 is released intact from caspase cleavage in cells undergoing apoptosis, thus preserving its immunogenicity. 119 We should also note that human and rat BECs express higher levels of Bcl-2 compared to other cells. 167, 168 PBC has been defined as a mucosal disease, based on the common involvement of other epithelia (mainly salivary glands) besides BECs. BECs, similar to other epithelial cells, secrete IgA and AMA-IgA have been detected in bile and other body fluids (including urine and saliva) from patients with PBC to react with PDC-E2. 169, 170 More recently, our group demonstrated the colocalization of AMA-IgA and PDC-E2, or a mimicking molecule, on the apical surface and in the cytoplasm of PBC-BECs. 171 To assess the direct pathogenicity of AMAIgA to BECs, Matsumura et al 172 incubated highly purified AMA-IgAs with canine kidney cells transfected with the human polymeric Ig receptor, inducing caspase upregulation and thus providing evidence of the direct proapoptotic effect.
The presence of aberrantly expressed PDC-E2-like antigens on the cell membrane of affected tissues was described in several studies; however, its precise definition and nature remain enigmatic. In fact, the mimicking protein is neither over-expressed in PBC liver, as shown by in situ hybridization of PDC-E2 mRNA, 131 nor has their expression on BEC membranes been definitely identified. 173 An apoptosis-induced modification can be hypothesized in the mechanism of apical expression, possibly mediated by a resulting alteration in cellular trafficking.
Concluding remarks and future directions
The genetic and immunological bases leading to PBC onset, perpetuation, and progression remain enigmatic, despite the growing body of evidence produced in the past decade. The autoimmune paradigm mutuated from other conditions seems to apply only in part to PBC, based, for example, on the lack of a consistent association with MHC haplotypes or the inefficacy of immunosuppressive treatments. To further complicate the picture, we cannot rule out at present that the genetic and etiological factors might be numerous, possibly specific to geographical areas, and separated from disease onset by a long period of time. The possible approaches to unraveling the genetic factors are several, 174 but in all cases the common factor must be an international collaboration effort to collect a large number of cases and controls or representative families. As for a better understanding of the immunopathogenesis of PBC, the discovery of representative animal models should be the priority to confirm existing or future theories. In particular, we encourage scientists from other disciplines to participate in our effort and to investigate their animal models for serum or histological signs of autoimmune cholestasis. Lastly, researchers in PBC should always be well aware of the clinical features of the disease, since their peculiarities might hold the key to the solution of the enigma. In conclusion, we have gone a long way in the study of PBC in the past years. The answer might be already out there; what remains to do is ask the right question to the right person.
